Bellerophon (BLPH) Receives a Buy from H.C. Wainwright

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Bellerophon (BLPH), with a price target of $30.00. The company’s shares closed last Monday at $8.60.

According to, Fein is a 5-star analyst with an average return of 12.7% and a 49.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Bellerophon has an analyst consensus of Moderate Buy, with a price target consensus of $30.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.85 and a one-year low of $3.26. Currently, Bellerophon has an average volume of 559.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts